- Home
- MBWM vs DAWN Comparison
MBWM vs DAWN Comparison
Compare MBWM & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBWM
- DAWN
- Stock Information
- Founded
- MBWM 1997
- DAWN 2018
- Country
- MBWM United States
- DAWN United States
- Employees
- MBWM N/A
- DAWN N/A
- Industry
- MBWM Major Banks
- DAWN Biotechnology: Pharmaceutical Preparations
- Sector
- MBWM Finance
- DAWN Health Care
- Exchange
- MBWM Nasdaq
- DAWN Nasdaq
- Market Cap
- MBWM 763.4M
- DAWN 624.8M
- IPO Year
- MBWM 1997
- DAWN 2021
- Fundamental
- Price
- MBWM $49.25
- DAWN $7.51
- Analyst Decision
- MBWM Buy
- DAWN Strong Buy
- Analyst Count
- MBWM 4
- DAWN 7
- Target Price
- MBWM $53.63
- DAWN $27.86
- AVG Volume (30 Days)
- MBWM 55.6K
- DAWN 2.1M
- Earning Date
- MBWM 10-14-2025
- DAWN 10-29-2025
- Dividend Yield
- MBWM 3.00%
- DAWN N/A
- EPS Growth
- MBWM N/A
- DAWN N/A
- EPS
- MBWM 5.03
- DAWN N/A
- Revenue
- MBWM $228,384,000.00
- DAWN $187,638,000.00
- Revenue This Year
- MBWM $10.34
- DAWN $12.56
- Revenue Next Year
- MBWM $11.93
- DAWN $48.02
- P/E Ratio
- MBWM $9.79
- DAWN N/A
- Revenue Growth
- MBWM 3.70
- DAWN 2190.50
- 52 Week Low
- MBWM $37.76
- DAWN $5.64
- 52 Week High
- MBWM $52.98
- DAWN $16.76
- Technical
- Relative Strength Index (RSI)
- MBWM 60.30
- DAWN 63.77
- Support Level
- MBWM $47.37
- DAWN $6.93
- Resistance Level
- MBWM $50.23
- DAWN $7.74
- Average True Range (ATR)
- MBWM 1.26
- DAWN 0.31
- MACD
- MBWM 0.36
- DAWN 0.12
- Stochastic Oscillator
- MBWM 81.65
- DAWN 87.43
About MBWM Mercantile Bank Corporation
Mercantile Bank Corp operates as a bank holding company. It offers various commercial banking services to individuals, businesses, governmental units, and other institutions. These services include deposit products such as checking, savings, and term certificate accounts and lending products such as commercial, residential mortgage, and installment loans. The company generates revenue from interest and dividends earned on loans, securities, and other financial instruments.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.